Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to 3068.97%.

  • CG Oncology's EBITDA Margin rose 627333600.0% to 3068.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 8285.33%, marking a year-over-year increase of 57456700.0%. This contributed to the annual value of 10067.25% for FY2024, which is 171136300.0% up from last year.
  • As of Q3 2025, CG Oncology's EBITDA Margin stood at 3068.97%, which was up 627333600.0% from 81161.54% recorded in Q1 2025.
  • CG Oncology's EBITDA Margin's 5-year high stood at 3068.97% during Q3 2025, with a 5-year trough of 1935500.0% in Q4 2023.
  • In the last 3 years, CG Oncology's EBITDA Margin had a median value of 23290.99% in 2024 and averaged 253606.61%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 2000000000bps in 2024, then crashed by -769140900bps in 2025.
  • Over the past 3 years, CG Oncology's EBITDA Margin (Quarter) stood at 1935500.0% in 2023, then skyrocketed by 100bps to 8344.08% in 2024, then skyrocketed by 63bps to 3068.97% in 2025.
  • Its EBITDA Margin was 3068.97% in Q3 2025, compared to 81161.54% in Q1 2025 and 8344.08% in Q4 2024.